MedPath

PS128 May Improve Off Duration on Parkinson's Disease

Not Applicable
Completed
Conditions
Parkinson Disease
Interventions
Dietary Supplement: daily ingestion of Lactobacillus plantarum PS128
Registration Number
NCT04389762
Lead Sponsor
Professor Lu Neurological Clinic
Brief Summary

The purpose of this study is to investigate the short term effects (12 Weeks) of Lactobacillus plantarum PS128 (PS128) on Parkinson's disease (PD) symptoms.

Detailed Description

This study is designed to examine the extent to which L. plantarum PS128 can improve symptoms in PD patients. L. plantarum PS128 is a psychobiotic that regulates the level of dopamine in specific brain regions. Patients with PD will receive PS128 treatment for 12 weeks. Symptoms of PD will be clinically evaluated before and after the treatment, and the results will be compared.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Patients diagnosed with idiopathic Parkinson's Disease
  • According to the record of ON / OFF diary for 3 consecutive days, the patient's daily off periods must be more than 3 hours a day.
  • Between ages of 40-80 years old.
Exclusion Criteria
  • Patients on antibiotics within the preceding one month
  • Patients using of other probiotic products (sachet, capsule or tablet) within the preceding two weeks
  • Have undergone surgery of liver, bladder, or gastrointestinal tract
  • Have current or history of inflammatory bowel disease
  • Have history of cancer
  • Known allergy to probiotics
  • Patients with comorbid dementia (Mini-Mental State Examination score ≤ 26) or major depression (The Beck Depression Inventory-II score ≥ 29)
  • Have received deep brain stimulation
  • Patients receiving artificial enteral or intravenous nutrition

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
PS128daily ingestion of Lactobacillus plantarum PS128daily ingestion of Lactobacillus plantarum PS128 capsules
Primary Outcome Measures
NameTimeMethod
Change in Unified Parkinson's Disease Rating Scale (UPDRS)Baseline to Week 12 assessed on medication

The UPDRS scores is a rating tool used to gauge the course of Parkinson's disease in patients. The minimum total score possible is 0 and the maximum total score possible is 199. Higher values represent a worse outcome.

Change in Unified Parkinson's Disease Rating Scale Part III (UPDRSIII)Baseline to Week 12 assessed both off and on medications

The UPDRS III scores is subscores of UPDRS, it indicates motor function of PD symptoms.

Change in Patient "ON-OFF" diary recordingRecord for 3 consecutive days prior to Baseline and Week 12 visits by patient-self

"ON-OFF" motor fluctuations are rapid changes in mobility during which PD patients report sudden shifts from adequate mobility to mobility, usually within a few seconds or minutes. The 24-hour diary is divided into 30-minute sections and only mark one answer for each half hour period. It is to know how much time each patient spends in the different Parkinson's states.

Secondary Outcome Measures
NameTimeMethod
Change in Patient Global Impression of Change (PGIC)Week 12 assessed on Medication

The PGIC consists of one item taken from the clinical global impression and adapted to the patient. The minimum total score possible is 1 and the maximum total score possible is 7. Higher values represent a worse outcome.

Change in Nonmotor Symptoms: 30-item Screening Questionnaire (NMS-Quest) ScoreBaseline to Week 12 assessed on Medication

NMS-Quest is a 30-item Screening tool for non-motor symptoms of Parkinson's disease. The minimum total score possible is 0 and the maximum total score possible is 30. Higher values represent a worse outcome.

Change in The Parkinson's Disease Questionnaire (PDQ-39)Baseline to Week 12 assessed on Medication

The Parkinson's Disease Questionnaire (PDQ-39) assesses how often people affected by Parkinson's experience difficulties across 8 dimensions of daily living including relationships, social situations and communication.

Trial Locations

Locations (1)

Professor Lu Neurological Clinic

🇨🇳

Taoyuan City, Guishan Dist., Taiwan

© Copyright 2025. All Rights Reserved by MedPath